SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
about
The NLPR3 inflammasome and obesity-related kidney disease.Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al.Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications.Recent novel approaches to limit oxidative stress and inflammation in diabetic complications.
P2860
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
SGLT-2 Inhibition with Dapagli ...... Saxagliptin, a DPP4 Inhibitor.
@en
type
label
SGLT-2 Inhibition with Dapagli ...... Saxagliptin, a DPP4 Inhibitor.
@en
prefLabel
SGLT-2 Inhibition with Dapagli ...... Saxagliptin, a DPP4 Inhibitor.
@en
P2093
P2860
P1476
SGLT-2 Inhibition with Dapagli ...... Saxagliptin, a DPP4 Inhibitor.
@en
P2093
Hsiu-Chiung Yang
Jose R Perez-Polo
Mandeep Bajaj
P2860
P304
P356
10.1007/S10557-017-6725-2
P577
2017-04-26T00:00:00Z